A Phase III, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
This is a Phase III, randomized study to evaluate the efficacy and safety of atezolizumab
compared with platinum-based chemotherapy consisting of a platinum agent (carboplatin or
cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel
(squamous disease) in highly PD-L1 expressed, chemotherapy-naïve, EGFR/ALK wild type patients
with stage IV non-squamous or squamous NSCLC.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.